James R. Berenson

Berenson Oncology, formally known as James R. Berenson, MD, Inc., is a specialized clinical research and healthcare entity focused on the treatment and study of multiple myeloma and related B-cell malignancies. Founded by Dr. James R. Berenson, the organization integrates a private medical practice with a robust clinical trials program and laboratory research through its affiliated Institute for Myeloma and Bone Cancer Research (IMBCR). The company provides comprehensive patient care while simultaneously developing novel therapeutic strategies and diagnostic tools, such as the soluble BCMA (sBCMA) biomarker. Berenson Oncology is recognized for its expertise in conducting early-phase clinical trials and its contributions to the approval of several landmark myeloma therapies.